The Effect of Vitamin K2 in Addition to Risedronate on the Patients with Postmenopausal Osteoporosis.

, Kim, Sang Beom; , Ryoo, Kyung Hyun; , Lee, Kyeong Woo; , Kwak, Hyun; , Yoon, Kisung

Original Article

Journal of the Korean Academy of Rehabilitation Medicine 2006;30(5):491-495.

Kim, Sang Beom , Ryoo, Kyung Hyun , Lee, Kyeong Woo , Kwak, Hyun , Yoon, Kisung

Department of Physical Medicine and Rehabilitation, Dong-A University College of Medicine, Korea. ryukh74@nate.com

리제드로네이트에 병합 투여한 비타민 K2의 효과

김상범, 류경현, 이경우, 곽현, 윤기성

동아대학교 의과대학 재활의학교실

Abstract

Objective
To assess the effect of vitamin K2 in addition to risedronate on postmenopausal osteoporosis
Method
We enrolled 21 postmenopausal osteoporosis women (age: 65.2⁑7.8 years). Ten subjects received risedronate (35 mg, weekly) and vitamin K2 (45 mg, daily) and eleven subjects only received risedronate. They all received calcium citrate 2,130 mg and vitamin D 600 IU daily. The duration of treatment was 7.7⁑1.4 months. Bone mineral density (BMD) of lumbar spine and both femurs, serum osteocalcin and urine deoxypyridinoline were examined at baseline and after treatment.
Results
After treatment, BMD, serum osteocalcin and urine deoxypyridinoline were improved in each group but there was no statistical difference between the groups.
Conclusion
There was no evidence of the benefit of vitamin K2 in addition to risedronate in bone metabolism on postmenopausal osteoporosis. (J Korean Acad Rehab Med 2006; 30: 491-495)

Key Words: Vitamin K2, Risedronate, Postmenopausal osteoporosis, Bone metabolism